“There is a moderate agreement between EHR data and Medicare Part D (MPD) claims data for the receipt of oral anticancer agents, which are a popular treatment option for cancer patients, according to a study published in JAMA Network Open. The study, conducted by the Texas Cancer Registry and The University of Texas MD Anderson Cancer Center (MDACC), found that 73.8 percent of the EHR data and MPD claims data overlapped, with 176 data sets shown in both and 123 sets not shown for either. Oral anticancer agents are becoming more popular and equally as expensive, leaving policymakers to uncover data about how patients use them, which then allows for …